Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders.

Journal of medicinal chemistry·2026

Same author

Effects of ketamine enantiomers on morphine and THC subjective effects in rats.

Journal of psychopharmacology (Oxford, England)·2025

Same author

Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated Withdrawal.

Cureus·2025

Same author

Fine-tuning 5-HT<sub>7</sub> receptor selectivity, inverse agonism, and metabolic stability of new (aryloxy)ethyl-piperidines toward antidepressant and pro-cognitive properties.

European journal of medicinal chemistry·2025

Same author

Analysis of rat vocalizations as a tool for assessing the effects of α7nAChR PAMs in a neurodevelopmental model of autism.

Behavioural brain research·2025

Same author

Salivary mitochondrial DNA is associated with biomarkers of Alzheimer's disease in cognitively normal older adults.

Translational psychiatry·2025

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Glutamate-based antidepressants: 20 years on.

Phil Skolnick¹, Piotr Popik, Ramon Trullas

¹Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA. phil.skolnick@nyumc.org

Trends in Pharmacological Sciences

|October 20, 2009

Summary

New glutamate-based therapies targeting N-methyl-D-aspartate (NMDA) receptors show promise for treating depression. These agents may offer a faster and more effective alternative to current serotonin and norepinephrine medications.

More Related Videos

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABA_A Receptor Presentation in the Rodent Brain

Published on: May 26, 2023

Related Experiment Videos

Last Updated: Jun 19, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain

BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABA_A Receptor Presentation in the Rodent Brain

Published on: May 26, 2023

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Depression affects over 120 million globally, often requiring long treatment durations.
Current biogenic amine-based antidepressants have limited efficacy, with only 60-65% of patients achieving symptom relief.
Treatment-resistant depression remains a significant clinical challenge.

Purpose of the Study:

To explore the potential of glutamate-based therapies for depression.
To review evidence supporting N-methyl-D-aspartate (NMDA) receptor antagonists as novel antidepressants.
To provide perspectives on the development of these emerging treatments.

Main Methods:

Review of recent research on NMDA receptor antagonists.
Analysis of clinical reports on traxoprodil and ketamine for depression.
Discussion of glutamate-based agents as alternatives to biogenic amine-based treatments.

Main Results:

NMDA receptor antagonists, particularly NR2B subtype antagonists, demonstrate antidepressant effects.
Traxoprodil shows efficacy in patients unresponsive to SSRIs.
Ketamine exhibits rapid and sustained antidepressant effects after single administration.

Conclusions:

Glutamate-based therapies represent a promising alternative for depression treatment.
Targeting the NMDA receptor offers a novel therapeutic strategy.
Further development of these agents could address unmet needs in depression management.